首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 109 毫秒
1.
将4个转录因子Oct4,Sox2,Klf4和c-Myc转入成纤维细胞可以生成诱导多能干细胞(iPS细胞),转录因子和染色质修饰因子在这个过程中起重要作用。LSD1作为染色质结构的调节因子,在早期胚胎发育和ES细胞分化中发挥着关键作用。为了探索LSD1在iPS细胞产生过程中的作用,首先比较了LSD1蛋白在MEFs和ES细胞中的表达量,然后分别通过在重编程体系中过表达LSD1、加入RNAi和抑制剂的方法探索LSD1的功能,最后用免疫共沉淀的方法初步发现LSD1的作用机制。结果表明,LSD1在ES细胞中的表达量高于MEFs中,过表达LSD1对iPS细胞的形成效率没有影响,而RNAi抑制LSD1的表达和LSD1抑制剂tranylcypromine都能促进iPS细胞的形成。免疫共沉淀实验表明LSD1和Oct4/Nanog有相互作用。这些数据说明LSD1通过和Oct4/Nanog相互作用调控iPS细胞的形成。  相似文献   

2.
自从2006年发现通过转入特定转录因子可使分化细胞重编程,iPSC的研究已经得到了极大的发展,人们在诱导方法、应用研究、潜在问题等方面进行了相当深入的探索。然而,到目前依然还有许多问题存在,具体的重编程机制依然不清楚,诱导干细胞与正常细胞的差异也愈加得到关注,其临床应用价值尚需需更多研究论证。  相似文献   

3.
诱导性多潜能干细胞(iPS细胞)的研究进展   总被引:1,自引:0,他引:1  
通过转染特定的基因组合可以将已分化的体细胞重编程为多潜能干细胞,这种干细胞称为诱导性多潜能干细胞(induced pluripotent stem cells,iPS cells)。这是近年来干细胞研究领域最令人瞩目的一项新的干细胞制备技术。iPS细胞的出现不仅为体细胞重编程去分化机制的研究提供了新的模型,而且为疾病发生发展相关机制研究与特异的细胞治疗带来了新的希望。就当前获取iPS细胞的方法、影响iPS细胞转化率和多能性维持的一些因素及其研究进展进行综述。  相似文献   

4.
通过外源转录调控因子的诱导,使成体细胞重编程为胚胎干细胞(ES细胞)样的多能细胞,这种细胞称为诱导多能干细胞(iPS细胞),这一方法被称为iPS技术。目前,iPS技术已先后在小鼠、人、猕猴、大鼠和猪中成功应用,建立了相应的iPS细胞系,并获得了iPS细胞嵌合小鼠和四倍体克隆小鼠。尽管iPS与ES细胞在形态和生长特性上有许多相同之处,但iPS细胞的建立需要较独特的诱导培养体系和鉴定方法。以下结合近年来iPS技术的发展和本实验室的相关研究,对iPS细胞的建立和培养体系的优化进行了深入探讨。  相似文献   

5.
将体细胞诱导为多功能干细胞为人类的再生医学提供了一个全新的研究手段,从而可以不用损坏胚胎就能获得可用于治疗各种特殊疾病的细胞。本文比较了近年来关于生成诱导性多能干细胞(induced pluripotent stem cells,iPS细胞)的诱导方法及重编程效率,总结了这些方法的共同点;另外通过对每个不同试验过程的影响因素进行比较,归纳了影响iPS细胞重编程过程的几个因素。  相似文献   

6.
通过病毒或非病毒转导体系,在小鼠和人的体细胞中人为表达几个与细胞多能性相关的转录因子,从而使细胞达到类似于胚胎干细胞(embryonic stem cells,ESCs)状态,是近年来新发展起来的体细胞重编程技术。这些被重编程的细胞称为诱导多能干细胞(induced pluripotent stem cells,iPS细胞)。这项技术为获得患者和疾病特异的多能干细胞提供了新的途径。患者和疾病特异的iPS细胞的获得,不仅在避免免疫排斥的宿主特异的细胞移植治疗上有广泛前景,并对了解疾病发生机理、药物筛选和毒性研究有着重要的意义。该文综述从iPS细胞技术的发明入手,着重讨论疾病iPS细胞的研究进展及其在应用于治疗时亟需解决的问题。  相似文献   

7.
体细胞通过重编程转变成其他类型的细胞,在再生医学方面具有重要的应用前景。细胞重编程的方法主要有体细胞核移植、细胞融合、细胞提取物诱导、限定因子诱导等,这些方法可以不同程度地改变细胞命运。最近,限定因子诱导的多能干细胞(induced pluripotent stem cell。iPS)为重编程提供了一种崭新的方法,不仅可以避免伦理争议,还提供了一种更为便利的技术,为再生医学开辟了新的天地;同时,iPS技术为研究基因表达调控、蛋白质互作、机体生长发育等提供了一个非常重要的研究手段。本文主要论述了体细胞重编程的方法及iPS细胞的进展、面临的问题和应用前景。  相似文献   

8.
低氧诱导因子家族研究进展   总被引:1,自引:0,他引:1  
低氧能诱导编码促红细胞生成素基因的转录,过程的具体分子机理一直不清。低氧诱导因子家族的克隆及其调控许多目的基因表达的发现,丰富了我们对机体氧感受的分子机理的认识。同时低氧诱导因子家族中各因子的表达差异,及其之间的相互调控,低氧诱导因子在低氧条件下的作用机理,对目的基因的调控及相互之间差异的阐明,对理解许多与组织缺氧有关的重要疾病如心血管疾病、中风、慢性阻塞性肺疾病,特别是肿瘤的病理生理过程有重要意义。  相似文献   

9.
脂多糖诱导的肿瘤坏死因子(LPS-induced TNF-α,LITAF),又称p53诱导基因7或溶酶体/晚期内体小膜内在蛋白。早期研究认为,p53蛋白的164~170位氨基酸肽段导入到人体单核细胞后可抑制LITAF的表达。近期研究发现,LITAF在LPS诱导的单核细胞或巨噬细胞中作为炎症细胞因子TNF-α的转录激活剂起作用,进而引发炎症。典型的LITAF结构域包含N-端的CXXC区、25个氨基酸长的疏水区和C-端的(H)XCXXC区。当机体受到LPS刺激后,LITAF疏水区结合到胞膜上,将N-端和C-端的CXXC区域连接在一起,形成紧密结合的Zn2+结构,此结构域诱导LITAF蛋白和STAT6(B)蛋白形成复合体进入细胞核,与TNF-α的启动子结合进而激活细胞因子TNF-α的转录表达,内源性增强机体清除肿瘤细胞或入侵病原的能力。该文就LITAF的结构和生物学功能的研究进展进行概述。  相似文献   

10.
诱导性多能干细胞(induced pluripotent stem cell,iPS cell)是通过转染外源特定的基因组合来诱导成体细胞重编程为类似于胚胎干细胞的一种多潜能干细胞,iPS细胞与胚胎干细胞不仅在形态上相似,而且在功能方面几乎相同.另外,iPS细胞的诞生克服了胚胎干细胞在临床应用时涉及的移植免疫排斥与伦理道德问题,因此具有重要的临床应用价值.目前iPS在治疗中枢神经系统性疾病方面的研究已取得很大进展,包括iPS细胞向神经细胞诱导分化方法的改进、分化机理的探索以及iPS细胞分化来源神经细胞在神经系统疾病模型中治疗作用的研究等.从iPS细胞的创建及特点、iPS细胞向神经细胞分化的诱导方法及研究新进展方面予以综述.  相似文献   

11.
12.
13.
14.
Neurodegenerative disease-specific induced pluripotent stem cell (iPSC) research contributes to the following 3 areas; “Disease modeling”, “Disease material” and “Disease therapy”.“Disease modeling”, by recapitulating the disease phenotype in vitro, will reveal the pathomechanisms. Neurodegenerative disease-specific iPSC-derived non-neuronal cells harboring disease-causative protein(s), which play critical roles in neurodegeneration including motor neuron degeneration in amyotrophic lateral sclerosis, could be “Disease material”, the target cell(s) for drug screening. These differentiated cells also could be used for “Disease therapy”, an autologous cellular replacement/neuroprotection strategy, for patients with neurodegenerative disease.Further progress in these areas of research can be made for currently incurable neurodegenerative diseases.  相似文献   

15.
王春生  张志人  朴善花  安铁洙 《遗传》2012,34(12):1545-1550
microRNA是调控基因转录后水平的一类长度约为22个核苷酸的非编码小分子RNA。大量研究证实, microRNAs广泛分布于真核生物, 其在细胞的分化发育、生长代谢等各种活动中都起着重要的调节作用。诱导多能性干细胞(Induced pluripotent stem cell, iPS)是将体细胞诱导成为具有胚胎干细胞性质的多潜能干细胞。iPS过程的核心为体细胞表观遗传状态发生重编程, 因此, 探明体细胞重编程机制对建立完善的iPS技术具有重要理论和实际意义。利用病毒载体将Oct4、Sox2、Klf4和c-Myc等因子导入体细胞的方法已不断发展, 但“基因组整合”及原癌基因的参与增加了诱导细胞的致癌率。随着使用腺病毒、质粒或蛋白诱导等“非整合型”方法及L-myc的替换均可获得具有多潜能性的干细胞, 癌变的风险大大降低。但其发生的理论机制仍不十分清楚。最近的研究证实, microRNAs影响体细胞的重编程过程, 特别是miR302/367、miR200、miR-34和miR290/295等家族的microRNAs在体细胞诱导为iPS过程中发挥重要作用。文章就近年microRNA在诱导多能干细胞中的作用进行综述。  相似文献   

16.
主要讨论了iPSCs的研究现状与应用前景。通过转入特定基因诱导体细胞重编程成为多能干细胞(pluripoterlt stem cells,PSCs)的研究成果,不仅为体细胞重编程去分化机制的研究注入了新的活力,而且为疾病发生发展相关机制研究与特异_的细胞治疗,特别是再生医学带来新的曙光。这种方法相对容易操作,比较稳定,在生物学基础研究和临床应用方面都具有潜在的价值。诱导性多能干细胞(iPSCs)的应用将是十分有益的,如创建人类疾病的遗传模型,培育转基因动物用于器官移植,改善动物生产性状和抗病性,以及生物制药等。另外iPSCs的产生对于解决长期以来干细胞研究领域的伦理问题和免疫排斥问题有巨大的意义,iPSCs结合基因治疗和细胞治疗的成果已经应用到了动物疾病模型上。然而,目前iPSCs技术要应用于临床还有很多工作要做。  相似文献   

17.
iPS细胞研究的新进展及应用   总被引:1,自引:0,他引:1  
Qin T  Miao XY 《遗传》2010,32(12):1205-1214
通过导入特定的转录因子可将分化的体细胞重编程为诱导性多能干细胞(Induced pluripotent stem cells,iPS cells),这项技术避免了干细胞研究领域的免疫排斥和伦理道德问题,是生命科学领域的一次巨大革命。与胚胎干细胞(Embryonic stem cells,ES cells)一样,iPS细胞能够自我更新并维持未分化状态,在体内可分化为3个胚层来源的所有细胞,进而参与形成机体所有组织和器官。在体外,iPS细胞可定向诱导分化出多种成熟细胞。因此,iPS细胞在理论研究和临床应用等方面都极具应用价值。文章对iPS细胞诱导的最新研究进展、iPS细胞诱导的不同方法,如何提高iPS细胞的制备效率和安全性,iPS细胞在基础研究以及临床研究等方面的应用进行了全面综述,并探讨了iPS细胞研究领域面临的问题以及该技术在转基因动物研究中的发展前景。  相似文献   

18.
Recent advances in stem cell technology have generated enthusiasm for their potential to study and treat a diverse range of human disease. Pluripotent human stem cells for therapeutic use may, in principle, be obtained from two sources: embryonic stem cells (hESCs), which are capable of extensive self-renewal and expansion and have the potential to differentiate into any somatic tissue, and induced pluripotent stem cells (iPSCs), which are derived from differentiated tissue such as adult skin fibroblasts and appear to have the same properties and potential, but their generation is not dependent upon a source of embryos. The likelihood that clinical transplantation of hESC- or iPSC-derived tissues from an unrelated (allogeneic) donor that express foreign human leucocyte antigens (HLA) may undergo immunological rejection requires the formulation of strategies to attenuate the host immune response to transplanted tissue. In clinical practice, individualized iPSC tissue derived from the intended recipient offers the possibility of personalized stem cell therapy in which graft rejection would not occur, but the logistics of achieving this on a large scale are problematic owing to relatively inefficient reprogramming techniques and high costs. The creation of stem cell banks comprising HLA-typed hESCs and iPSCs is a strategy that is proposed to overcome the immunological barrier by providing HLA-matched (histocompatible) tissue for the target population. Estimates have shown that a stem cell bank containing around 10 highly selected cell lines with conserved homozygous HLA haplotypes would provide matched tissue for the majority of the UK population. These simulations have practical, financial, political and ethical implications for the establishment and design of stem cell banks incorporating cell lines with HLA types that are compatible with different ethnic populations throughout the world.  相似文献   

19.
Stem cells possess the ability to self-renew and differentiate into other cell types. In vivo, stem cells reside in their own anatomic niches in a defined physiological environment, from which they are released to differentiate into a required cell type when deemed appropriate. While a resident within the niche, the stem cell receives signals that in turn maintain the cell in a pluripotent state. In addition, the niche also provides nourishment to the cell. Physically, the niche also serves to anchor the cell via various ECM components and cell-adhesion molecules. Therefore, in vitro models that replicate the in vivo niche will lead to a better understanding of stem cell fate and turnover. In turn, this will help inform attempts to culture stem cells in vitro on artificial niche-like substrates. In this review, we have highlighted recent studies describing artificial niche-like substrates used to culture embryonic and induced pluripotent stem cells in vitro.  相似文献   

20.
Induced pluripotent stem(i PS) cells, somatic cells reprogrammed to the pluripotent state by forced expression of defined factors, represent a uniquely valuable resource for research and regenerative medicine. However, this methodology remains inefficient due to incomplete mechanistic understanding of the reprogramming process. In recent years, various groups have endeavoured to interrogate the cell signalling that governs the reprogramming process, including LIF/STAT3, BMP, PI3 K, FGF2, Wnt, TGFβ and MAPK pathways, with the aim of increasing our understanding and identifying new mechanisms of improving safety, reproducibility and efficiency. This has led to a unified model of reprogramming that consists of 3 stages: initiation, maturation and stabilisation. Initiation of reprogramming occurs in almost all cells that receive the reprogramming transgenes; most commonly Oct4, Sox2, Klf4 and c Myc, and involves a phenotypic mesenchymal-to-epithelial transition. The initiation stage is also characterised by increased proliferation and a metabolic switch from oxidative phosphorylation to glycolysis. The maturation stage is considered the major bottleneck within the process, resulting in very few "stabilisation competent" cells progressing to the final stabilisation phase. To reach this stage in both mouse and human cells, pre-i PS cells must activate endogenous expression of the core circuitry of pluripotency, comprising Oct4, Sox2, and Nanog, and thus reach a state of transgene independence. By the stabilisation stage, i PS cells generally use the same signalling networks that govern pluripotency in embryonic stem cells. These pathways differ between mouse and human cells although recent work has demonstrated that this is context dependent. As i PS cell generation technologies move forward, tools are being developed to interrogate the process in more detail, thus allowing a greater understanding of this intriguing biological phenomenon.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号